Bausch Health (NYSE: BHC) was negatively impacted by the COVID-19 pandemic as most of its products are dependent on elective medical procedures or patient choices. Sales of its contact lenses dipped amid pandemic-related restrictions as did revenue from medical devices and surgical systems as surgeries and medical procedures were deferred.
The trends have improved since then as restrictions eased and the company is seeing a recovery in its business, which was evident in its third quarter 2021 performance. However, there are still some risks that persist. Take a look at this report to get an idea of the areas where Bausch sees opportunities for growth and which factors are likely to impact its performance in the near term.
The Bausch Health Companies market research report covers key aspects about the firm including company profile, financial highlights and recent key developments. The report is meant as a resource for investors to form a 360 degree understanding about the firm.
Table of Contents
- Financial Highlights
- SWOT Analysis
- Business Segment Analysis
- Strategic Drivers
- Key Stock Holders
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales
Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to